FDA Approves Eli Lilly's Onswik Once-Weekly Insulin for Type 2 Diabetes
The US regulator granted approval for the drugmaker's basal insulin therapy, providing patients with an alternative to daily injections.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
2 publishers have covered this in 2 articles since 25 Sept 2026. STAT published first, on 25 September at 15:25 UTC; MedPageToday.com - medical news for physicians followed 3h 57m later. The most recent article, from MedPageToday.com - medical news for physicians, appeared on 25 September at 19:22 UTC.
Outlets reporting it: STAT, MedPageToday.com - medical news for physicians.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- FDA
- Eli Lilly
- Onswik